Home › Multipel myeloom › Illinois › Chicago
Multipel myeloom klinische studies in Chicago, IL
22 studies voor Multipel myeloom zoeken deelnemers op locaties in en rond Chicago (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
RekruterenFase 1
- University of Chicago Medical Center /ID# 278863, Chicago
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekruterenFase 3
- Research Site, Chicago
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RekruterenFase 1/2
- University of Chicago Medical Center, Chicago
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RekruterenFase 3
- Rush University System for Health, Chicago
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RekruterenFase 3
- University Of Illinois Medical Center, Chicago
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RekruterenFase 4
- Northwestern University, Chicago
- University of Chicago, Chicago
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
RekruterenFase 2
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekruterenFase 2
- Cancer Treatment Centers of America-Chicago, Chicago
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruterenFase 2
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
RekruterenFase 2
- University of Illinois at Chicago, Chicago
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RekruterenFase 3
- Endeavor Health - Swedish Hospital, Chicago
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RekruterenFase 3
- Advocate Illinois Masonic Medical Center, Chicago
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekruterenFase 1/2
- Research Site, Chicago
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RekruterenFase 3
- Research Site, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
Rekruteren
- Northwestern University Feinberg School of Medicine, Chicago
Personalized Autologous Transplant for Multiple Myeloma
RekruterenFase 1
- University Illinois Chicago, Chicago
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekruterenFase 3
- University of Chicago, Chicago
- University of Illinois Medical Center at Chicago, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekruterenFase 1
- University of Chicago, Chicago
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RekruterenFase 1
- University of Chicago Medical Center, Chicago
Hypofractionation (Radiation) Trial for Multiple Myeloma
RekruterenFase 1
- The University of Chicago Comprehensive Cancer Center, Chicago
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekruterenFase 1/2
- Northwestern, Chicago
Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
RekruterenFase 1
- University of Illinois Cancer Center, Chicago
Multipel myeloom studies in andere steden
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- Rochester, MN24 studies
- St. Louis, MO24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Seattle, WA22 studies
Andere studies in Chicago
- Niet-kleincellige longkanker61 studies
- Borstkanker58 studies
- Kanker (alle vormen)51 studies
- Metastatische kanker45 studies
- Prostaatkanker45 studies
- Obesitas41 studies
- Longkanker41 studies
- Eierstokkanker36 studies
- Beroerte34 studies
- Colorectale kanker33 studies
- Hartfalen31 studies
- Overgewicht28 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.